Online citations, reference lists, and bibliographies.
← Back to Search

The Risk Of Secondary Malignancies Over 30 Years After The Treatment Of Non‐hodgkin Lymphoma

L. Brown, R. Howard, L. Travis
Published 2006 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Tward et al. reported a significantly elevated risk of mesothelioma in a population-based study of survivors of non-Hodgkin lymphoma who were treated with radiation. Although the authors were not aware of other population-based studies that describe an increased risk of mesothelioma after irradiation, we reported a significantly elevated relative risk (RR) of mesothelioma among irradiated testicular cancer patients (RR, 4.0; 95% confidence interval [95% CI], 2.0–8.1; 14 cases). Herein, we provide to our knowledge the first description of significant excesses of mesothelioma (40 cases) among 376,825 breast cancer patients who had survived for 1 year and were reported to population-based cancer registries in Sweden, Denmark, Finland, and Norway between January 1, 1943 and December 31, 2002. The estimated average doses of radiation received by the ipsilateral lung/pleura range from 15.1 to 15.5 gray (Gy) based on the standard tangential (medial and lateral) and anterior supraclavicular treatment fields (that delivered a tumor dose of 40 to 50 Gy) used to treat breast cancer during the study period. We found a significantly elevated risk of mesothelioma (standard incidence ratio [SIR] of 1.42; 95% CI, 1.02–1.94). Excesses began 10 years after a diagnosis of breast cancer, with the highest risk (SIR of 5.60; 95% CI, 2.05–12.21; 6 patients) observed at 30 years of follow-up, a temporal pattern that was consistent with the late effects of radiation. Risk was most pronounced for women diagnosed before 1970 (SIR of 2.46; 95% CI, 1.51–3.81; 20 cases). SIRs for the subset of 22 breast cancer patients reported to registries that record treatment data were 1.78 (95% CI, 1.00–2.95; 15 cases) for those who initially received radiotherapy compared with 0.95 (95% CI, 0.38–1.97; 7 cases) for whom radiotherapy was not recorded. Treatment regimens for breast cancer have undergone substantial changes over the past several decades, and therefore the evaluation of long-term survivors often reflects the effects of therapies that have subsequently been modified. Nonetheless, our findings add to the growing body of evidence that large doses of radiation might be associated with excess mesotheliomas, although analytic studies are required to establish a causal relation.
This paper references



This paper is referenced by
10.1007/s00417-020-04896-1
Second primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body
A. Alfaar (2020)
10.1016/j.ajpath.2010.10.039
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.
D. Jean (2011)
10.1182/blood-2009-05-219071
Consistency and synergy.
Mary Jane Teta (2009)
10.1016/B978-1-4377-1398-5.10001-3
The epidemiology of cancer and aging
K. Clough-Gorr (2012)
10.3390/ijerph9124744
Second Malignant Neoplasms Following Radiotherapy
S. Kumar (2012)
10.1097/JTO.0b013e3182199819
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
10.3844/AMJSP.2012.240.248
The Role of Inflammation in Development and Therapy of Malignant Mesothelioma
Jill M. Miller (2012)
10.1111/bjh.12684
Age‐time risk patterns of solid cancers in 60 901 non‐Hodgkin lymphoma survivors from Finland, Norway and Sweden
J. Lorenzo Bermejo (2014)
10.1007/s10552-009-9357-4
Ionizing radiation: a risk factor for mesothelioma
J. Goodman (2009)
10.1177/2324709618785934
One Pulmonary Lesion, 2 Synchronous Malignancies
M. Aqeel (2018)
10.1002/ijc.31801
Second primary cancers in non‐Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction
S. Chattopadhyay (2018)
[Occupational respiratory cancers].
J. Pairon (2008)
10.1007/s12094-020-02322-w
The risk of malignancies in patients receiving hematopoietic stem cell transplantation: a systematic review and meta-analysis
K. Heydari (2020)
10.21873/anticanres.14140
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells
T. Shukuya (2020)
10.14288/1.0390430
Characterization of environmental and genetic factors in multiple-case lymphoid cancer families
S. J. Jones (2020)
10.1371/journal.pone.0105919
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
R. Kanteti (2014)
10.1080/10428190701447346
Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma
J. Tward (2007)
10.3109/10428194.2010.529207
Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma
J. Hasskarl (2011)
Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII
Roberto Weinstein (2015)
10.1201/b13277
Drug-induced and Iatrogenic Respiratory Disease
P. Camus (2010)
10.1002/cncr.22526
Therapeutic radiation for lymphoma
M. J. Teta (2007)
10.1002/cncr.32513
Risk and subtypes of secondary primary malignancies in diffuse large B‐cell lymphoma survivors change over time based on stage at diagnosis
A. Major (2019)
10.1007/978-3-642-15742-4_31
Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases
P. Camus (2010)
10.1007/s11060-008-9703-5
Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience
S. Jabbour (2008)
10.1586/era.11.88
The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again
R. Bindra (2011)
10.1016/S0761-8425(08)71517-1
Cancers respiratoires professionnels
Jean-Claude Pairon (2008)
Lymphomes et cancers synchrones : de la clinique à la biologie
C. Delette (2016)
10.1007/978-1-4471-6479-1_14
Radiation Therapy for Non-melanoma Skin Cancer in Immunosuppressed Patients and Cutaneous Toxicity from This Therapy
A. Currey (2014)
10.1080/10428190701636468
The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era
A. Wirth (2007)
10.1097/CCO.0b013e32832f3c8b
Localized large cell lymphoma: is there any need for radiation therapy?
D. Persky (2009)
10.2147/OTT.S100214
The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma
Abdel-Ghani M. Azzouqa (2016)
10.1093/annonc/mdq697
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis.
M. Pirani (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar